Alosetron for irritable bowel syndrome

BMJ

Volumn 326, Issue 7379, 2003, Pages 51-

  Palmer, James B D ^a   Palmer, Robert H ^b  

^a GLAXOSMITHKLINE   (United States)

^b Forest Laboratories   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85007724464     PISSN: 09598138     EISSN: 14685833     Source Type: Journal    
DOI: 10.1136/bmj.326.7379.51/b     Document Type: Letter

References (5)

1. Moynihan R. Alosetron: a case study in regulatory capture, or a victory for patients' rights? BMJ 2002; 325: 592–595
2. Lièvre M. Alosetron for irritable bowel syndrome. BMJ 2002; 325: 555–556
3. Lièvre M. Alosetron for irritable bowel syndrome. BMJ 2002; 325: 555. (14 September.)
4. Moynihan R. Alosetron: a case study in regulatory capture, or a victory for patients' rights? BMJ 2002; 325: 592. (14 September.)
5. Gastrointestinal Drugs Advisory Committee and Drug Safety and Risk Management Subcommittee of the Advisory Committee for Pharmaceutical Science, April 23, 2002. http://www.fda.gov/ohrms/dockets/ac/02/transcripts/3848T1.pdf (accessed 26 Nov 2002).